JP5176418B2 - Branched chain amino acid beverage - Google Patents
Branched chain amino acid beverage Download PDFInfo
- Publication number
- JP5176418B2 JP5176418B2 JP2007193004A JP2007193004A JP5176418B2 JP 5176418 B2 JP5176418 B2 JP 5176418B2 JP 2007193004 A JP2007193004 A JP 2007193004A JP 2007193004 A JP2007193004 A JP 2007193004A JP 5176418 B2 JP5176418 B2 JP 5176418B2
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- chain amino
- amino acid
- branched chain
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000005693 branched-chain amino acids Chemical class 0.000 title claims description 30
- 235000013361 beverage Nutrition 0.000 title claims description 25
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 21
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 15
- 229960000310 isoleucine Drugs 0.000 claims description 13
- 229930182844 L-isoleucine Natural products 0.000 claims description 12
- 229960003136 leucine Drugs 0.000 claims description 11
- 229960004295 valine Drugs 0.000 claims description 11
- 241000208688 Eucommia Species 0.000 claims description 9
- 235000019454 L-leucine Nutrition 0.000 claims description 8
- 239000004395 L-leucine Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 241000202807 Glycyrrhiza Species 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 5
- 229940088679 drug related substance Drugs 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 1
- 235000017803 cinnamon Nutrition 0.000 claims 1
- 125000001990 thiamine group Chemical class 0.000 claims 1
- 235000019645 odor Nutrition 0.000 description 33
- 238000012360 testing method Methods 0.000 description 24
- 239000007788 liquid Substances 0.000 description 21
- 239000000284 extract Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 241000411851 herbal medicine Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- -1 amino acid compound Chemical class 0.000 description 2
- 239000012512 bulk drug substance Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 2
- 150000003544 thiamines Chemical class 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000202722 Bupleurum falcatum Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241000336315 Cistanche salsa Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940045613 taurine 1000 mg Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seasonings (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、分岐鎖アミノ酸を配合した飲料において、経時的に発生する不快臭が軽減された飲料に関する。 The present invention relates to a beverage in which an unpleasant odor generated over time is reduced in a beverage containing a branched chain amino acid.
アミノ酸は重要な栄養素であり、医薬品、医薬部外品、食品などに広く配合されている。生体内で合成できないヒトの必須アミノ酸のうち、バリン、ロイシン、イソロイシンの3種は、分岐鎖を有する構造上の類似点から総称して分岐鎖アミノ酸と称されている。分岐鎖アミノ酸は筋肉内で代謝され、筋肉の働きと深く関わっているといわれている。分岐鎖アミノ酸は運動することにより筋肉内で消費され、不足すると筋肉疲労、筋肉痛等の原因になり、慢性の摂取不足は足腰の筋力低下や腰痛の原因にもなるといわれている。 Amino acids are important nutrients and are widely used in pharmaceuticals, quasi drugs, foods and the like. Of the essential human amino acids that cannot be synthesized in vivo, three types of valine, leucine, and isoleucine are collectively referred to as branched chain amino acids because of their structural similarity with branched chains. Branched-chain amino acids are metabolized in the muscle and are said to be deeply related to the function of the muscle. It is said that branched chain amino acids are consumed in the muscles by exercising, and shortage causes muscle fatigue, muscle pain, etc., and chronic inadequate intake also causes muscle weakness and back pain in the legs and lower back.
しかし、分岐鎖アミノ酸は、溶液中において経時的にアミノ酸に固有の不快臭を発生させるため、風味の点で満足できるものではなかった。そのため、従来の分岐鎖アミノ酸が配合された液剤は、分岐鎖アミノ酸の配合量が十分なものではなかった。 However, since branched chain amino acids generate an unpleasant odor inherent to amino acids over time in a solution, they are not satisfactory in terms of flavor. For this reason, conventional liquid agents containing a branched chain amino acid have not had a sufficient amount of the branched chain amino acid.
従来、不快な風味を有するアミノ酸配合液剤の風味改善技術として、不快な風味を有するビタミンB1誘導体を配合する技術(特許文献1参照)などが開示されている。 Conventionally, as a technique for improving the flavor of an amino acid compound solution having an unpleasant flavor, a technique for blending a vitamin B1 derivative having an unpleasant flavor (see Patent Document 1) and the like have been disclosed.
本発明は、分岐鎖アミノ酸を配合した飲料において、分岐鎖アミノ酸に固有の経時的に発生する不快臭を抑制し、分岐鎖アミノ酸配合飲料の風味を改善することを目的とする。 An object of the present invention is to suppress an unpleasant odor inherent in branched-chain amino acids over time in beverages containing branched-chain amino acids and improve the flavor of the branched-chain amino acid-containing beverages.
本発明者らは、課題を解決するために種々検討した結果、経時的に臭いが発生し、商品性が低下する高濃度の分岐鎖アミノ酸を配合した飲料に、特定の生薬を特定量配合することにより、経時的に発生する不快臭が抑制できることを見いだし、本発明を完成した。 As a result of various investigations to solve the problems, the present inventors formulated a specific amount of a specific herbal medicine into a beverage containing a high concentration of branched-chain amino acids that generate odors over time and reduce the commercial value. Thus, it was found that an unpleasant odor generated over time can be suppressed, and the present invention has been completed.
すなわち、本発明は
(1)(a)110mg/50mL以上の濃度の分岐鎖アミノ酸、並びに(b)原生薬換算で50mg/50mL以上の濃度の、サイコ、トチュウ、トシシ、ニクジュヨウ及びケイヒから選ばれる一種又は二種以上、を配合したことを特徴とする飲料、
(2)分岐鎖アミノ酸が、L-バリン、L-ロイシン及びL-イソロイシンから選ばれる一種又は二種以上である(1)記載の飲料、
(3)(a)110〜2800mg/50mLの濃度のL-バリン、100〜1100mg/50mLの濃度のL-ロイシン、又は、80〜2000mg/50mLの濃度のL-イソロイシン、並びに(b)原生薬換算で50mg/50mL以上の濃度の、サイコ、トチュウ、トシシ、ニクジュヨウ及びケイヒから選ばれる一種又は二種以上、を配合したことを特徴とする飲料、
(4)分岐鎖アミノ酸の濃度が160mg/50mL以上である(1)〜(3)のいずれかに記載の飲料、
(5)さらにビタミンB1類を配合した(1)〜(4)のいずれかに記載の飲料、
(6)pHが2〜6である(1)〜(5)のいずれかに記載の飲料、
(7)原生薬換算で50mg/50mL以上の濃度の、サイコ、トチュウ、トシシ、ニクジュヨウ及びケイヒから選ばれる一種又は二種以上を配合したことを特徴とする、110mg/50mL以上の濃度で分岐鎖アミノ酸を配合した飲料において経時的に生じる不快臭を低減させる方法、
である。
That is, the present invention is selected from (1) (a) a branched-chain amino acid having a concentration of 110 mg / 50 mL or more, and (b) psycho, eucommia, toshishi, licorice and keihi having a concentration of 50 mg / 50 mL or more in terms of a drug substance. A beverage characterized by blending one or more,
(2) The beverage according to (1), wherein the branched chain amino acid is one or more selected from L-valine, L-leucine and L-isoleucine,
(3) (a) L-valine at a concentration of 110-2800 mg / 50 mL, L-leucine at a concentration of 100-1100 mg / 50 mL, or L-isoleucine at a concentration of 80-2000 mg / 50 mL, and (b) the drug substance A beverage characterized by containing one or more selected from psycho, eucommia, toshi, licorice and keihi in a concentration of 50 mg / 50 mL or more in terms of conversion,
(4) The beverage according to any one of (1) to (3), wherein the concentration of the branched chain amino acid is 160 mg / 50 mL or more,
(5) The beverage according to any one of (1) to (4), further containing vitamin B1
(6) The beverage according to any one of (1) to (5), wherein the pH is 2 to 6.
(7) A branched chain at a concentration of 110 mg / 50 mL or more, characterized in that it contains one or more selected from Psycho, Eucommia, Toshishi, Nikujuyou, and Keihi at a concentration of 50 mg / 50 mL or more in terms of active ingredient. A method for reducing unpleasant odors that occur over time in beverages containing amino acids,
It is.
本発明により、分岐鎖アミノ酸を高濃度で飲料に配合しても、経時的な不快臭の発生を抑制することができた。 According to the present invention, it was possible to suppress the generation of unpleasant odor over time even when a branched chain amino acid was blended in a beverage at a high concentration.
本発明において、分岐鎖アミノ酸とは、L-バリン、L-ロイシン、L-イソロイシンを好ましいものとしてあげることができるが、それぞれDL体、D体を用いた場合についても本発明の効果が得られることが見込まれる。 In the present invention, preferred examples of the branched chain amino acid include L-valine, L-leucine, and L-isoleucine, but the effects of the present invention can also be obtained when DL and D forms are used. It is expected.
本発明の分岐鎖アミノ酸の配合量は、経時的に不快臭を発生する量であり、分岐鎖アミノ酸を単独で用いる場合には、内服液剤全体で50mLあたり、L-バリンは110〜2800mg、L-ロイシンは100〜1100mg、L-イソロイシンは80〜2000mgである。分岐鎖アミノ酸の配合量が少ない場合、経時的な不快臭はあまり感じないので本発明は不要であり、分岐鎖アミノ酸の配合量が多すぎると溶解度が不十分なため製品としての提供が困難になるからである。ここで、2種以上の分岐鎖アミノ酸を混合して用いる場合は、分岐鎖アミノ酸の合計量が内服液剤全体で50mLあたり、110mg以上配合すると一部の被験者がアミノ酸の不快臭を感じ、160mg以上配合すると被験者の約半分がアミノ酸の不快臭を感じ、240mg以上配合するとほぼ全ての被験者がアミノ酸の不快臭を感じることも見出した。 The blended amount of the branched chain amino acid of the present invention is an amount that generates an unpleasant odor over time. When the branched chain amino acid is used alone, L-valine is 110 to 2800 mg per L in 50 ml of the whole oral solution. -Leucine is 100-1100 mg and L-isoleucine is 80-2000 mg. If the amount of branched chain amino acid is small, the unpleasant odor over time is not felt so much, so the present invention is unnecessary.If the amount of branched chain amino acid is too large, the solubility is insufficient and it is difficult to provide as a product. Because it becomes. Here, when two or more kinds of branched chain amino acids are used as a mixture, when the total amount of branched chain amino acids is 110 mg or more per 50 mL of the whole oral solution, some subjects feel an unpleasant odor of the amino acid, and 160 mg or more It was also found that about half of subjects felt an unpleasant odor of amino acids when blended, and almost all subjects felt an unpleasant odor of amino acids when blended in an amount of 240 mg or more.
本発明に用いる生薬は、サイコ、トチュウ、トシシ、ニクジュヨウ又はケイヒであるが、本発明ではそれらの生薬の1種または2種以上を任意に組み合わせて用いることもできる。 The herbal medicine used in the present invention is psycho, eucommia, toshi, licorice or keihi, but in the present invention, one or more of these herbal medicines can be used in any combination.
本発明のサイコはセリ科(Umbelliferae)のミシマサイコ(Bupleurum falcatumL.)又はその変種の根もしくは全草を起源とし、トチュウはトチュウ科(Eucommiaceae)のトチュウ(Eucommia ulmoides Oliver)の樹皮を起源とし、トシシはヒルガオ科のハマネナシカズラ(マメダオシ)(Cuscuta chinensis LAM.)の種子を起源とし、ニクジュヨウはハマウツボ科の寄生植物ホンオニクCistanche salsaを起源とし、ケイヒはクスノキ科(Lauraceae)のケイ (Cinnamomum cassia Blume)又はその同属植物の樹皮、又は周皮の一部を除いたものを起源とする。 The psycho of the present invention originates from the root or whole plant of the Umbelliferae (Bupleurum falcatum L.) or its varieties, and the eucommia originates from the bark of the Eucommmiaceae Eucommiaaceum, Is originated from the seeds of Cuscuta chinensis LAM., Nikujuyou originated from the parasitoid Cistanche salsa of the clover family, and Kahi is Cinnamomum cassia Blume or Lauraceae It originates from the bark of the same genus plant, or from a part of the pericarp.
本発明で用いる生薬の配合量は、飲料全体で50mLあたり、原生薬換算量で50〜500mgが好ましく、200〜500mgの範囲がより好ましい。本発明で用いる生薬を組み合わせて用いるときはそれらの生薬の合計量がこの範囲内であれば効果を有する。 The blending amount of the crude drug used in the present invention is preferably 50 to 500 mg, more preferably in the range of 200 to 500 mg per 50 mL of the whole beverage in terms of the crude drug equivalent. When the crude drugs used in the present invention are used in combination, it is effective if the total amount of these crude drugs is within this range.
本発明で配合する生薬は、エキスの形態での配合が好ましい。エキスの製造は通常の方法、例えば、抽出溶媒を用いて、適当な温度(低温又は加熱)にて、粉砕した生薬原料から抽出する方法などにより行う。抽出溶媒は生薬に応じて適当に選択できるが、好ましくは、水、親水性溶媒(特にエタノール)およびこれらの混合溶媒が用いられる。本発明のエキスは、液状抽出物をそのまま使用することができるほか、水などで希釈したもの、液状抽出物の濃縮物、液状抽出物の乾固物としても使用できる。すなわち、本発明のエキスには、乾燥エキス、軟エキス、流エキス、チンキなどいずれのものも包含される。 The herbal medicine blended in the present invention is preferably blended in the form of an extract. The extract is produced by an ordinary method, for example, a method of extracting from a crushed crude drug raw material at an appropriate temperature (low temperature or heating) using an extraction solvent. The extraction solvent can be appropriately selected depending on the crude drug, but preferably water, a hydrophilic solvent (especially ethanol) and a mixed solvent thereof are used. The extract of the present invention can be used as a liquid extract as it is, or can be used as a diluted product of water or the like, a concentrate of a liquid extract, or a dried product of a liquid extract. That is, the extract of the present invention includes any of dry extract, soft extract, flow extract, tincture and the like.
本発明の飲料は、不快臭を抑制する効果の点からpHは酸性側が好ましく、pH2〜6の範囲がさらに好ましく、pH2.5〜5が特に好ましい。ここでpH調整は、可食性の酸をpH調整剤として用いることができる。pH調整剤としては、クエン酸、リンゴ酸、酒石酸、フマル酸、乳酸、コハク酸、アスコルビン酸、酢酸などの有機酸及びそれらの塩類、塩酸、リン酸などの無機酸及びそれらの塩類などがあげられる。これらのpH調整剤は一種又は二種以上使用できる。 From the viewpoint of the effect of suppressing unpleasant odor, the beverage of the present invention is preferably on the acidic side, more preferably in the range of pH 2 to 6, and particularly preferably pH 2.5 to 5. Here, pH adjustment can use an edible acid as a pH adjuster. Examples of the pH adjuster include citric acid, malic acid, tartaric acid, fumaric acid, lactic acid, succinic acid, ascorbic acid, acetic acid and other organic acids and salts thereof, hydrochloric acid and phosphoric acid and other inorganic acids and salts thereof, and the like. It is done. These pH adjusters can be used alone or in combination.
また、分岐鎖アミノ酸と同時にビタミンB1類を配合すると、経時的にさらに強い不快臭が発生することがわかったが、本発明ではそのような不快臭に対しても有効であることも見出した。ここで、ビタミンB1類とはチアミン又はその塩(硝酸チアミン、塩酸チアミンなど)、チアミン誘導体(ジセチアミン、フルスルチアミン、オクトチアミンなど)などがあげられる。 In addition, it was found that when vitamin B1 was added at the same time as the branched chain amino acid, a stronger unpleasant odor was generated over time, but the present invention has also been found to be effective against such unpleasant odor. Here, vitamin B1 includes thiamine or a salt thereof (thiamine nitrate, thiamine hydrochloride, etc.), a thiamine derivative (discetiamine, fursultiamine, octothiamine, etc.) and the like.
本発明の飲料には、さらに各種ビタミン類、アミノ酸及びその塩類、その他の生薬及び生薬抽出物、甘味剤、保存剤、矯味剤、着色剤など飲料で一般に使用される成分を配合することができる。 In the beverage of the present invention, various vitamins, amino acids and salts thereof, other herbal medicines and herbal extracts, sweeteners, preservatives, corrigents, coloring agents, and other ingredients commonly used in beverages can be further blended. .
本発明の飲料は、常法により調製でき、その方法は特に制限はされないが、通常、各成分を規定量以下の精製水にて混合、溶解し、精製水にて規定量に容量調整し、必要に応じて濾過、滅菌処理をすることにより得られる。なお、脂溶性ビタミンを含むときは、通常用いられる界面活性剤により乳化、可溶化剤などで可溶化、または分散剤により懸濁させることもできる。 The beverage of the present invention can be prepared by a conventional method, and the method is not particularly limited, but usually each component is mixed and dissolved in a specified amount or less of purified water, and the volume is adjusted to a specified amount with purified water, Obtained by filtration and sterilization as necessary. When the fat-soluble vitamin is contained, it can be emulsified with a commonly used surfactant, solubilized with a solubilizer, or suspended with a dispersant.
実施例
以下に、実施例および試験例により本発明の効果を詳細に説明する。なお、各生薬エキスは購入したものを用い、配合量は原生薬換算量で示した。
Examples Hereinafter, the effects of the present invention will be described in detail with reference to Examples and Test Examples. In addition, each crude drug extract used what was purchased, and the compounding quantity was shown by the amount equivalent to the crude drug.
比較例1
L−イソロイシン 100mg
L−ロイシン 240mg
L−バリン 80mg
L−アルギニン塩酸塩 300mg
タウリン 1000mg
ビタミンB1硝酸塩 5.65mg
安息香酸ナトリウム 30mg
クエン酸 200mg
砂糖 3000mg
ポリビニルピロリドンK29/32 500mg
希塩酸(pH調節剤) 適量(pH3.2)
上記処方を精製水に溶解し、希塩酸でpH3.2に調整後、精製水で50mLになるよう調製し、80℃で30分滅菌して液剤を得た。
Comparative Example 1
L-isoleucine 100mg
L-leucine 240mg
L-valine 80mg
L-arginine hydrochloride 300mg
Taurine 1000mg
Vitamin B1 nitrate 5.65mg
Sodium benzoate 30mg
Citric acid 200mg
3000mg sugar
Polyvinylpyrrolidone K29 / 32 500mg
Dilute hydrochloric acid (pH regulator) Appropriate amount (pH 3.2)
The above formulation was dissolved in purified water, adjusted to pH 3.2 with diluted hydrochloric acid, adjusted to 50 mL with purified water, and sterilized at 80 ° C. for 30 minutes to obtain a liquid.
比較例1の処方にサイコ流エキス 500mg(原生薬換算量)を配合した処方で、比較例1と同様に調製し液剤を得た。 A liquid preparation was obtained in the same manner as in Comparative Example 1 except that 500 mg (powder equivalent amount) was added to the prescription in Comparative Example 1.
実施例1のサイコ流エキスをトチュウ葉抽出液 500mg(原生薬換算量)に変更した処方で、比較例1と同様に調製して液剤を得た。 A liquid preparation was obtained in the same manner as in Comparative Example 1 with the prescription in which the psycho-flow extract of Example 1 was changed to 500 mg of eucommia leaf extract (concentration in bulk drug substance).
実施例1のサイコ流エキスをトシシエキス 500mg(原生薬換算量)に変更した処方で、比較例1と同様に調製して液剤を得た。 A liquid preparation was obtained in the same manner as in Comparative Example 1 with the prescription in which the psycho-flow extract of Example 1 was changed to 500 mg of Toshishi extract (concentration in bulk drug substance).
実施例1のサイコ流エキスをニクジュヨウエキス 500mg(原生薬換算量)に変更した処方で、比較例1と同様に調製して液剤を得た。 A liquid preparation was obtained in the same manner as in Comparative Example 1 with the prescription in which the psycho-flow extract of Example 1 was changed to 500 mg of citrus extract (raw material equivalent amount).
実施例1のサイコ流エキスをケイヒ流エキス 500mg(原生薬換算量)に変更した処方で、比較例1と同様に調製して液剤を得た。 A liquid preparation was obtained in the same manner as in Comparative Example 1 with the prescription in which the psycho-type extract of Example 1 was changed to 500 mg of the Keihi-type extract (the amount equivalent to the drug substance).
比較例2〜18
実施例1のサイコ流エキスを表1に示した各生薬エキスに変更した処方で、実施例1と同様に調製して液剤を得た。
Comparative Examples 2-18
A liquid preparation was obtained in the same manner as in Example 1, except that the psycho-flow extract of Example 1 was changed to each herbal extract shown in Table 1.
試験例1
実施例、比較例の各液剤を65℃5日間保存した液剤について、不快臭の程度を6人のパネルにより評価した。比較例1の生薬を配合しない処方を対照とし、実施例、比較例の各液剤を下記に示す採点法(5点評価法)による官能試験を行い、それぞれの平均点を算出した。結果を表1に示した(表の結果値は各パネルの平均値)。
Test example 1
About the liquid agent which preserve | saved each liquid agent of an Example and a comparative example at 65 degreeC for 5 days, the grade of the unpleasant odor was evaluated by the panel of 6 persons. Using the prescription containing no crude drug of Comparative Example 1 as a control, each liquid preparation of Examples and Comparative Examples was subjected to a sensory test by the scoring method (5-point evaluation method) shown below, and the average score was calculated. The results are shown in Table 1 (result values in the table are average values of each panel).
なお、各パネルには5点評価法により評価してもらい、平均値を100点法に換算して表に示した。不快臭の評価基準は以下のとおりである:100(コントロールと同じ)、80(コントロールより僅かに弱い)、60(コントロールよりやや弱い)、40(コントロールよりとても弱い)、20(コントロールより非常に弱い)、0(臭わない) Each panel was evaluated by a 5-point evaluation method, and the average value was converted into a 100-point method and shown in the table. The evaluation criteria for unpleasant odor are as follows: 100 (same as control), 80 (slightly weaker than control), 60 (slightly weaker than control), 40 (very weaker than control), 20 (much weaker than control) Weak), 0 (no smell)
実施例6〜9、試験例2
実施例1のサイコ流エキスを、生薬種類、配合量を表に記載のものに変更した処方で実施例1と同様に液剤を製造し、65℃5日間保存した液剤について5人のパネルにより試験例1と同様の官能試験を行った。生薬種類、配合量及び試験結果を表2に示した。
Examples 6-9, Test Example 2
A liquid preparation was prepared in the same manner as in Example 1 with the prescription in which the type of herbal medicine and the blending amount were changed to those shown in the table, and the liquid preparation stored at 65 ° C. for 5 days was tested by a panel of 5 persons. The same sensory test as in Example 1 was performed. Table 2 shows the types of herbal medicines, blending amounts, and test results.
試験例3
L−イソロイシン 100mg、各生薬200mg(原生薬換算量)を精製水に溶解し、クエン酸でpHを3.2に調製後、精製水で50mLになるよう調製し、80℃で30分滅菌して液剤を得た。
Test example 3
L-isoleucine 100 mg and each crude drug 200 mg (raw drug equivalent amount) are dissolved in purified water, adjusted to pH 3.2 with citric acid, adjusted to 50 mL with purified water, and sterilized at 80 ° C. for 30 minutes. To obtain a solution.
65℃5日間保存した液剤について、生薬未配合処方の不快臭と比較し、5人のパネルにより試験例1と同様の官能試験を行った。配合生薬及び試験結果を表3に示した。 About the liquid agent preserve | saved at 65 degreeC for 5 days, compared with the unpleasant odor of a crude drug unblended prescription, the sensory test similar to Test Example 1 was done by the panel of five persons. Table 3 shows the combination crude drugs and test results.
表から明らかなように、本発明の生薬類は不快臭を抑制していたが、ケイヒが特に強いL−イソロイシン由来の不快臭抑制効果を有することがわかった。 As apparent from the table, the herbal medicines of the present invention suppressed the unpleasant odor, but it was found that Keihi has a particularly strong L-isoleucine-derived unpleasant odor suppressing effect.
試験例4
試験例3で製造した処方のL−イソロイシンを、L−ロイシン 240mgに変更した処方で液剤を製造し、65℃5日間保存した液剤について、試験例3と同様に官能試験を行った。配合生薬及び試験結果を表4に示した。
Test example 4
In the same manner as in Test Example 3, a sensory test was carried out on the liquid preparation prepared by changing the L-isoleucine prepared in Test Example 3 to 240 mg L-leucine and storing it at 65 ° C. for 5 days. Table 4 shows the combination crude drugs and test results.
表から明らかなように、本発明の生薬類は不快臭を抑制していたが、特にニクジュヨウが強いL−ロイシン由来の不快臭抑制効果を有することがわかった。 As is apparent from the table, the herbal medicines of the present invention suppressed the unpleasant odor, but it was found that the herbal odor is particularly effective for suppressing the unpleasant odor derived from L. leucine.
試験例5
試験例3で製造した処方のL−イソロイシンを、L−バリン 80mgに変更した処方で液剤を製造し、65℃5日間保存した液剤について、試験例3と同様に官能試験を行った。配合生薬及び試験結果を表5に示した。
Test Example 5
In the same manner as in Test Example 3, a sensory test was performed on the liquid prepared by changing the L-isoleucine prepared in Test Example 3 to 80 mg of L-valine and storing the solution at 65 ° C. for 5 days. Table 5 shows the combination crude drugs and test results.
表から明らかなように、本発明の生薬類はL−バリン由来の不快臭を強く抑制していた。 As is apparent from the table, the herbal medicines of the present invention strongly suppressed the unpleasant odor derived from L-valine.
参考例1
下記処方を精製水に溶解し、希塩酸でpHを3.2に調整した。精製水で全量50mLに調整し、80℃で30分滅菌して参考処方1及び2の液剤を製造した。
Reference example 1
The following formulation was dissolved in purified water, and the pH was adjusted to 3.2 with dilute hydrochloric acid. The total amount was adjusted to 50 mL with purified water, and sterilized at 80 ° C. for 30 minutes to prepare liquids of Reference Formulas 1 and 2.
参考試験1
参考処方1を65℃5日保存した液剤について、4人のパネルにより不快臭の強さを、9点評価法による官能評価を行い、平均点を算出した。評価は、非常に弱い:1点、やや弱い:3点、どちらでもない:5点、やや強い:7点、非常に強い:9点とした。その結果、平均点は6.5点であったことから、保存後の参考処方1は不快臭を有することがわかった。
Reference test 1
About the liquid agent which preserve | saved Reference prescription 1 at 65 degreeC for 5 days, the sensory evaluation by the 9-point evaluation method was performed for the strength of the unpleasant odor with the panel of 4 persons, and the average score was computed. Evaluation was very weak: 1 point, somewhat weak: 3 points, neither: 5 points, slightly strong: 7 points, very strong: 9 points. As a result, since the average score was 6.5 points, it was found that Reference Formula 1 after storage had an unpleasant odor.
参考試験2
参考処方1及び2を65℃5日保存し、そのときの参考処方1を対照とし、参考処方2の液剤について対照と比較した不快臭の強さを、4人のパネルによる9点評価法により官能評価を行い、平均点を算出した。評価は、コントロールより弱い:0点、コントロールと同じ:1点、コントロールよりやや強い:3点、コントロールより強い:5点、コントロールよりとても強い:7点、コントロールより非常に強い:9点の9段階評価を行った。
Reference test 2
Reference formulations 1 and 2 were stored at 65 ° C. for 5 days, and the reference formulation 1 at that time was used as a control. Sensory evaluation was performed and the average score was calculated. Evaluation is weaker than control: 0 points, same as control: 1 point, slightly stronger than control: 3 points, stronger than control: 5 points, very strong than control: 7 points, very strong than control: 9 points 9 A stage evaluation was performed.
その結果、平均点は5.5であり、参考処方2のビタミンB1を配合した処方では、明らかに不快臭が強くなっていた。 As a result, the average score was 5.5, and the unpleasant odor was clearly strong in the prescription containing the vitamin B1 of Reference Prescription 2.
参考例2
下記処方を精製水に溶解し、希塩酸でpHを3.2に調整した。精製水で全量50mLに調整し、80℃で30分滅菌して参考処方3〜8の液剤を製造した。
Reference example 2
The following formulation was dissolved in purified water, and the pH was adjusted to 3.2 with dilute hydrochloric acid. The total amount was adjusted to 50 mL with purified water, and sterilized at 80 ° C. for 30 minutes to produce solutions of Reference Formulas 3-8.
参考試験3
参考処方3〜8を50℃3日保存した液剤について、4人のパネルにより不快臭が気になり始めるアミノ酸濃度を評価軸上(サンプル間の軸上での距離は配合濃度に比例する)に感覚で矢印を記載して示してもらい、各パネルの平均点を算出した。各パネルの数値を以下に示した。
Reference test 3
For solutions prepared by storing Reference Formulas 3 to 8 at 50 ° C for 3 days, the amino acid concentration at which the unpleasant odor begins to be worrisome by a panel of 4 people is on the evaluation axis (the distance on the axis between samples is proportional to the concentration of the mixture) The average score of each panel was calculated by having an arrow written in the sense. The numerical value of each panel is shown below.
分岐鎖アミノ酸の合計量が内服液剤全体で50mLあたり、約110mg程度以上配合すると不快臭を感じ出し、160mg以上配合するとパネルの平均で不快臭を感じ、240mg以上配合するとほぼ全てのパネルが不快臭を感じることがわかった。 When the total amount of branched chain amino acids is about 110 mg or more per 50 mL of the total internal solution, unpleasant odor is felt, when 160 mg or more is blended, the panel feels unpleasant odor, and when 240 mg or more is blended, almost all panels are unpleasant. I understood that I felt.
参考例3
下記処方を精製水に溶解し、希塩酸でpHを3.2に調整した。精製水で全量50mLに調整し、80℃で30分滅菌して参考処方9〜18の液剤を製造した。
Reference example 3
The following formulation was dissolved in purified water, and the pH was adjusted to 3.2 with dilute hydrochloric acid. The total amount was adjusted to 50 mL with purified water, and sterilized at 80 ° C. for 30 minutes to produce solutions of Reference Formulas 9-18.
参考試験4
参考処方3及び9〜17を50℃3日保存した液剤について、各アミノ酸ごとに4人のパネルにより不快臭が気になり始めるアミノ酸濃度を評価軸上(サンプル間の軸上での距離は配合濃度に比例する)に感覚で矢印を記載して示してもらい、各パネルの平均点を算出した。各パネルの数値を以下に示した。
Reference test 4
For solutions prepared by storing Reference Formulas 3 and 9 to 17 at 50 ° C. for 3 days, the amino acid concentration at which each person begins to worry about an unpleasant odor by a panel of 4 people is on the evaluation axis (the distance on the axis between the samples is blended) The average point of each panel was calculated. The numerical value of each panel is shown below.
その結果、濃度評価値の平均は、L-イソロイシンで159mg、L-ロイシンで111mg、L-バリンで124mgであり、この濃度付近もしくはそれ以上の高い濃度の場合に各アミノ酸の不快臭が発生することが明らかとなった。 As a result, the average of the concentration evaluation values is 159 mg for L-isoleucine, 111 mg for L-leucine, and 124 mg for L-valine, and an unpleasant odor of each amino acid is generated at a concentration near or higher than this concentration. It became clear.
本発明の飲料は、例えば健康飲料、栄養補給飲料などの各種食品、ドリンク剤、シロップ剤などの医薬品や医薬部外品に適用できる。 The beverage of the present invention can be applied to, for example, various foods such as health drinks and nutritional supplement drinks, pharmaceuticals such as drinks and syrups, and quasi drugs.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007193004A JP5176418B2 (en) | 2006-07-25 | 2007-07-25 | Branched chain amino acid beverage |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006201386 | 2006-07-25 | ||
JP2006201386 | 2006-07-25 | ||
JP2007193004A JP5176418B2 (en) | 2006-07-25 | 2007-07-25 | Branched chain amino acid beverage |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008050349A JP2008050349A (en) | 2008-03-06 |
JP5176418B2 true JP5176418B2 (en) | 2013-04-03 |
Family
ID=39234715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007193004A Active JP5176418B2 (en) | 2006-07-25 | 2007-07-25 | Branched chain amino acid beverage |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5176418B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5359527B2 (en) * | 2008-04-30 | 2013-12-04 | 大正製薬株式会社 | Beverage |
JP6300154B2 (en) * | 2014-03-14 | 2018-03-28 | ハウスウェルネスフーズ株式会社 | Beverage containing star anise extract |
US10912663B2 (en) | 2014-11-26 | 2021-02-09 | S.T.S. Medical Ltd. | Shape change structure for treatment of nasal conditions including sinusitis |
JP7000877B2 (en) * | 2018-01-25 | 2022-01-19 | 味の素株式会社 | Manufacturing method of foods containing amino acids |
JP7360784B2 (en) * | 2018-06-27 | 2023-10-13 | 小林製薬株式会社 | pharmaceutical composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10287551A (en) * | 1997-04-11 | 1998-10-27 | Taisho Pharmaceut Co Ltd | Liquid agent for internal use improved in unpleasant flavor of amino acid |
JPH11209266A (en) * | 1998-01-22 | 1999-08-03 | Taisho Pharmaceut Co Ltd | Internal liquid medicine haying reduced bitterness |
JP2006016358A (en) * | 2004-07-02 | 2006-01-19 | Dai Ichi Seiyaku Co Ltd | Anti-fatigue formulation |
JP2006089430A (en) * | 2004-09-27 | 2006-04-06 | Taisho Pharmaceut Co Ltd | Aqueous solution composition containing biotin and vitamin b2 |
-
2007
- 2007-07-25 JP JP2007193004A patent/JP5176418B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008050349A (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI517793B (en) | Contains the composition of imidazole peptides and quercetin glycosides | |
US8137712B2 (en) | Rehydration beverage | |
JP5176418B2 (en) | Branched chain amino acid beverage | |
JP5110314B2 (en) | Sleep improving composition and sleep improving agent | |
AT513274B1 (en) | Dietary supplements | |
JPH0614746A (en) | Health beverage | |
JP2011148776A (en) | Liquid preparation composition | |
JP6519248B2 (en) | Crude drug extract-containing beverage | |
JP2009536167A (en) | Xanthone derivatives for the treatment of muscle disorders | |
JP7460352B2 (en) | Liquid or semi-solid compositions | |
AU2020371091A1 (en) | Functional beverage comprising collagen | |
JP2019199406A (en) | Black turmeric including composition for improving male function, black turmeric including composition for anti-aging of skin, black turmeric including composition for improving antioxidant, use thereof and mixed food product including black turmeric including composition | |
JP4645842B2 (en) | Royal jelly-containing beverage composition | |
JP4645841B2 (en) | Royal jelly-containing beverage composition | |
US6465021B2 (en) | Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease | |
JP4697123B2 (en) | Royal jelly-containing beverage composition | |
RU2160586C1 (en) | Biologically active admixture of general strengthening action | |
JP5359527B2 (en) | Beverage | |
EP1563743B1 (en) | Composition comprising a caffeine-containing substance, particularly guarana | |
KR101076693B1 (en) | Additive for Deacidifying Soluble Calcium Products | |
JP2019142781A (en) | Composition for preventing getting drunk | |
JP6528362B2 (en) | Beverage | |
RU2247516C1 (en) | Dietary biologically active additive | |
RU2423889C1 (en) | Beverage having detoxicant action | |
JP6323453B2 (en) | Oral solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121211 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5176418 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160118 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |